2015 VAM: 3521 - ADT: Frontiers in Obstructive Airway Therapies
The Asthma Diagnosis and Treatment Interest Section Forum addresses recent advances in monoclonal antibodies for the practicing allergist and how these therapies may be used in the future. Multiple new therapies have been developed and FDA approved for COPD and in addition recent trials by ACRN and other groups have demonstrated the effectiveness of once a day LABA and LAMA in asthma. The presentation includes an update on use of the newer anticholinergic and once a day LABA for use in asthma. This recording also addresses the need to screen for alpha-1-antitrypsin deficiency. Presently, only 10% of patients with alpha-1 deficiency have been identified and many of these patients present as asthma and can respond to augmentation with alpha-1.
AMA PRA Category 1 CreditsTM: 1.25
Credit must be claimed by June 30, 2017. Any credit request on or after July 1, 2017 will be subject to an administrative fee.
System requirements: Two most recent versions of Internet Explorer, Safari, Google Chrome, and Firefox
Allied Health Professionals
Upon completion of this activity, participants will be able to:
1. Describe recent advances in monoclonal therapies in development and how they may affect asthma care
2. Summarize newer therapies recently approved by the FDA for obstructive lung disease and their potential use in asthma
3. Demonstrate improved identification of alpha-1 antitrypsin deficiency and review the recent advances in replacement therapy for the deficiency
Dr. Elliot Israel, MD FAAAAI, Brigham and Women's Hospital, Boston, MA
Dr. Reynold A. Panettieri Jr., MD, University of Pennsylvania, Philadelphia, PA
Dr. Charlie Strange III, MD, Medical University of South Carolina, Charleston, SC
- 1.25 AttendanceAttendance credit.
- 1.25 CECE credit.
- 1.25 CMECME credit.